AKT1 and non-small cell lung carcinoma: This finding integrates with previous knowledge that PI3K/AKT inhibition represents a potential therapeutic strategy, as GDC-0941 has shown promising outcomes in clinical trials, particularly in breast cancer and non-small cell lung cancer (41–43).